Business Performance Review

Q2 FY24 | Highlights Dr. Yasir Rawjee Managing Director & Chief Executive Officer REVENUE 5,954 (IN MILLIONS) EBITDA (IN MILLIONS) PAT (IN MILLIONS) 1,725 1,187 16.9% 2.9% YoY QoQ 12.2% YoY (11.5%) QoQ 11.1% YoY (12.3%) QoQ "I am pleased to share that we continue to deliver remarkable growth, propelled by a robust GPL business and steady external API business. Geographically, regulated markets including the US, Europe, LATAM and India continue to spearhead our growth. In light of the announced change in ownership, I see this development as a pivotal opportunity to augment our standing in the API industry and continue the trajectory characterised by growth and healthy margins. Looking ahead, enhanced visibility towards the H2FY24 demand for our generic API and CDMO business bolsters our confidence of delivering growth in FY24" GLS registered a revenue from operations of ₹ 5,954 Mn for Q2FY24, recording a strong growth of 16.9% YoY and 2.9% QoQ Gross Margins improved in Q2FY24 trending at 54.1%, up 120 bps YoY; EBITDA margins at 29.0% down 120 bps YoY; driven by better gross margin and higher employee expense Revenue from Generic API business was Rs. 5,428 Mn, up 19.7% YoY whereas CDMO business revenue was Rs. 253 Mn, down 18.1% YoY Generated strong free cash flow of Rs. 1,535 Mn leading to Cash and Cash Equivalents as of 30th September 2023 at Rs. 4,430 Mn GLS: Glenmark Life Sciences; GPL: Glenmark Pharmaceuticals Ltd. (parent co.) 3 Є Glenmark LIFE SCIENCES

View entire presentation